vimarsana.com

Page 2 - நிறுவனம் ஆஃப் அணு மருந்து கூட்டணி அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr Reddy s Laboratories announces commercial launch of anti-COVID 2-DG drug

COVID-19 patients: Dr Reddy Labs launches 2-DG oral anti-COVID drug commercially

Synopsis In the initial weeks, the company will make the drug available in hospitals across metros and tier I cities, and subsequently expand coverage to the rest of India. The price for the drug has been pegged at Rs. 990 for private procurements while for government supply, a subsidized rate will be offered. Agencies It can be administered only upon prescription and under the supervision of a qualified physician to hospitalised moderate to severe COVID-19 patients as an adjunct therapy to the existing standard of care. Drug major Dr Reddy s Laboratories on Monday announced the commercial launch of COVID-19 treatment drug, 2-deoxy-D-glucose (2-DG), at a maximum retail price of Rs 990 per sachet.

Dr Reddy s announces commercial launch of 2-DG

Updated: MRP of each sachet ₹990, to be offered at subsidised rate to govt institutions Share Article AAA An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. The drug will help in faster recovery of Covid-19 patients. Twitter/@DRDO India   MRP of each sachet ₹990, to be offered at subsidised rate to govt institutions Drugmaker Dr. Reddy’s Laboratories has announced the commercial launch of 2-deoxy-D-glucose (2-DG), an oral drug for use as an adjunct therapy for hospitalised COVID-19 patients. The maximum retail price is ₹990 per sachet. It will be made available at a subsidised rate to government institutions, the company said, adding its 2-DG has a purity of 99.5%.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.